On August 26, 2019, seven promising start-ups kick-off their BII journey with the Business Acceleration Academy bootcamp. The accepted start-ups are building their company on technologies such as CRISPR, data-driven AI, developing antidepressant drugs and bone reconstruction.
The academy is an intense program over three months where the start-ups do a 360-degree analysis of their individual cases to explore the commercial potential of their project. To help them advance, BII has an experienced team of business developers, mentors and experts that will guide them through the working sessions on market analysis, competitors, IP and regulatory and much more.
“Out of many, very qualified projects, our selection committee has chosen three start-ups in medtech, three in pharma and two in industrial biotech. With prior batches, we have seen how the teams evolve immensely during the program and we expect them to have a clear plan to execute on once they graduate”, says Monika Luniewska Jensen, Senior Business Developer at BioInnovation Institute.
Meet the seven teams in the Business Acceleration Academy:
TrachFlush: An automatic upper airway secretion removal system for ventilated patients
EMBIO: Patient-centric, bio-enhanced bone reconstruction
MedicQuant: Enabling rapid lifesaving decisions for patients
Lophora: Developing rapid-acting drugs for treatment-resistant depression
IBIO Tech: Advancing diagnostic solutions and therapies for autoimmune diseases
Caffeine: Generate designs and analyse your strain engineering project without writing a single line of code
GEBAMO: Better therapeutics and diagnostics based on CRISPR-Cas12a technology
If you are interested in exploring the commercial potential of your project, BII has an open call for the Business Acceleration Academy. Read more and apply today.
More news from BII
Professor at AU: BII grant is key to solidify our idea
Event: Talks at the Square with Martin Bonde